Program
MTX-463
A development code.
Its studies are mostly in Idiopathic Pulmonary Fibrosis, led by Mediar Therapeutics.
Furthest: phase 2, since Apr 14, 20253 company-led studies, 1 open or runningNext primary completion: Aug 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Mediar Therapeutics | 31 open or running | phase 2since Apr 14, 2025 | Apr 22, 2024 | Aug 2027phase 2 · NCT06967805 |
Also a collaborator on its studies: icon-plc.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 22, 2024First study: phase 1 study in HealthyFirst studyNCT06401213 · 56 enrolled · United States
- Apr 14, 2025Phase 2 study in Idiopathic Pulmonary FibrosisNCT06967805 · 168 enrolled · United States, Argentina, Australia and more
- Feb 10, 2026Phase 1 study in Healthy Adult MaleNCT07450521 · 8 enrolled · United States
Ahead
- Aug 2027Primary completion: phase 2 study in Idiopathic Pulmonary FibrosisNCT06967805
TargetBeta
CCN4 →read by rule
“MTX-463 is an immunoglobin G1 (IgG1) monoclonal antibody directed against WNT-inducible signaling pathway protein 1 (WISP1).”study text, by rule · the study
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07450521Healthy Adult Male · United States | 1 | Completed | Mar 11, 2026 | 8 |
| NCT06967805Idiopathic Pulmonary Fibrosis · United States, Argentina, Australia and more | 2 | Active, not recruiting | Aug 2027 | 168 |
| NCT06401213Healthy · United States | 1 | Completed | Nov 15, 2024 | 56 |
How it is read
Names in the registry
- “MTX-463”, 3 entries
Codes read as this program: MTX463.
Conditions, from the studies’ own filings
- Idiopathic Pulmonary Fibrosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.